ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Construction Needs From NCI Said $40 Million Year For Four Years

June 9, 1978

In Brief: Magnuson Delays Action On Apparitions Bill; No Vote See Now Until September

July 28, 1978

NIH Policy On Diversity In Sponsored Meetings

June 16, 1995

Von Eschenbach Presents His “2015 Goal” As Logical Progression of Cancer Program (Interview)

May 16, 2003

DCT Counselors Ponder Coordination, New Opportunities

December 12, 1975

Can NCI Fund 4-Year Grants With 2-Year Stimulus Funds?

March 6, 2009